- Home
- HCWB vs TXMD Comparison
HCWB vs TXMD Comparison
Compare HCWB & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- TXMD
- Stock Information
- Founded
- HCWB 2018
- TXMD 2008
- Country
- HCWB United States
- TXMD United States
- Employees
- HCWB N/A
- TXMD N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- TXMD Health Care
- Exchange
- HCWB Nasdaq
- TXMD Nasdaq
- Market Cap
- HCWB 16.1M
- TXMD 17.1M
- IPO Year
- HCWB 2021
- TXMD N/A
- Fundamental
- Price
- HCWB $4.44
- TXMD $1.18
- Analyst Decision
- HCWB Strong Buy
- TXMD
- Analyst Count
- HCWB 1
- TXMD 0
- Target Price
- HCWB $35.00
- TXMD N/A
- AVG Volume (30 Days)
- HCWB 236.1K
- TXMD 69.5K
- Earning Date
- HCWB 08-13-2025
- TXMD 08-11-2025
- Dividend Yield
- HCWB N/A
- TXMD N/A
- EPS Growth
- HCWB N/A
- TXMD N/A
- EPS
- HCWB N/A
- TXMD N/A
- Revenue
- HCWB $1,445,145.00
- TXMD $1,841,000.00
- Revenue This Year
- HCWB N/A
- TXMD $427.09
- Revenue Next Year
- HCWB N/A
- TXMD N/A
- P/E Ratio
- HCWB N/A
- TXMD N/A
- Revenue Growth
- HCWB N/A
- TXMD 53.55
- 52 Week Low
- HCWB $3.55
- TXMD $0.70
- 52 Week High
- HCWB $100.80
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- HCWB 28.61
- TXMD 47.25
- Support Level
- HCWB $4.05
- TXMD $1.11
- Resistance Level
- HCWB $5.77
- TXMD $1.22
- Average True Range (ATR)
- HCWB 0.49
- TXMD 0.09
- MACD
- HCWB -0.07
- TXMD 0.00
- Stochastic Oscillator
- HCWB 9.98
- TXMD 42.31
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.